Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EPS (Basic): 2023-2025

Historic EPS (Basic) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$0.33.

  • Monte Rosa Therapeutics' EPS (Basic) fell 13.79% to -$0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 117.58%. This contributed to the annual value of -$0.98 for FY2024, which is 62.74% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its EPS (Basic) stood at -$0.33 for Q3 2025, which was down 120.00% from -$0.15 recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' EPS (Basic) ranged from a high of $0.57 in Q1 2025 and a low of -$0.71 during Q2 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median EPS (Basic) value was -$0.43 (recorded in 2024), while the average stood at -$0.32.
  • Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' EPS (Basic) was 207.55% (2025), while the steepest drop was 13.79% (2025).
  • Monte Rosa Therapeutics' EPS (Basic) (Quarterly) stood at -$0.57 in 2023, then spiked by 140.35% to $0.23 in 2024, then decreased by 13.79% to -$0.33 in 2025.
  • Its last three reported values are -$0.33 in Q3 2025, -$0.15 for Q2 2025, and $0.57 during Q1 2025.